Closing thoughts for XXXX .

@entity1 @entity73 @entity146
The wide-ranging field of cognition enhancing research along with its ethics as it stands today is summarized. In the forefront are potentially novel drugs and non-pharmacological treatments for @entity73 across many different @entity146 . Today's research will bring new drugs to @entity1 tomorrow, and tomorrow's research will bring new molecular targets to clinical development that should be cognitive domain-specific. There is the likelihood that special populations may be better treated and that personalized medicine for @entity73 could become a reality. It is conceivable that with the current research effort, cognition enhancing drugs will become available to wide-ranging populations of @entity1 with @entity146 and to those that are healthy. In some cultures, there is a push in society to be more intelligent or have more cognitive prowess. Thus, the ethical use of cognitive enhancing drugs should be an area of debate and communication. Neuroethics is a growing field and it intends to bring together key contributors such as physicians, disease experts, regulatory officials, and policy makers to discuss how such medicines can or should be made available. Together with this, one has to consider the possibility that no single medicine or technology will have a great impact on cognition and, therefore, combination therapy of drugs plus other approaches like exercise or transcranial direct-current stimulation may be the path forward. This is another area of scientific inquiry and debate, and the results should be fruitful and helpful to @entity1 . The science of cognition is advancing at a rapid rate, and communication of its progress along with the development of rational and ethical policies for use of @entity73 will be beneficial.
